ISPOR - EE190 Cost-Effectiveness of Dapagliflozin Alone or in Combination with Saxagliptin Added to Standard of Care for the Management of Diabetic Kidney Disease in the United States

EE190 Cost-Effectiveness of Dapagliflozin Alone or in Combination with Saxagliptin Added to Standard of Care for the Management of Diabetic Kidney Disease in the United States

Abstract

Authors

T Abegaz S Fatimah V Diaby AA Ali

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 7S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now